{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:52:30Z","timestamp":1787507550716,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The clinical benefit of broad-spectrum empiric therapy in patients with acute cholangitis is unclear. We aimed to evaluate the impact of broad-spectrum and narrow-spectrum empiric therapies on patient outcomes using a Japanese claims database. The study included patients who were diagnosed with acute cholangitis between April 2014 and August 2022, aged 18\u201399 years, received antibiotics, had blood cultures collected, and underwent biliary drainage. Patients who received empiric therapy with carbapenems, piperacillin\/tazobactam, or fourth-generation cephalosporins were included in the broad-spectrum group, whereas others were included in the narrow-spectrum group. Of the 4,755 eligible patients, 3,377 were categorized into the narrow-spectrum group and 1,378 into the broad-spectrum group. In the multivariate logistic regression analysis, older age, higher Charlson Comorbidity Index, the presence of sepsis, and intensive care unit admission were associated with increased 30-day in-hospital mortality, whereas the receipt of broad-spectrum empiric therapy was not (adjusted odds ratio, 1.37 [95% confidence interval {CI}, 0.84\u20132.23]). In the propensity score matching analysis, there was also no association between the receipt of broad-spectrum empiric therapy and 30-day in-hospital mortality (odds ratio, 1.43 [95% CI, 0.82\u20132.50]). Furthermore, in the propensity score-matched cohort, the broad-spectrum group had longer duration of intravenous antibiotic therapy (median interquartile range [IQR]: 8 [6 \u201311] day vs. 9 [7 \u201313] day; difference 1 day [95% CI, 0.31\u20131.69 day]) and length of hospital stay (median [IQR]: 13 [9 \u201320] day vs. 16 [11 \u201325] day; difference 3 day [95% CI, 1.87\u20134.13 day]), compared with the narrow-spectrum group. In this large-scale study using a Japanese claims database, broad-spectrum empiric therapy was not associated with improved clinical outcomes, compared with narrow-spectrum empiric therapy. Therefore, the necessity of broad-spectrum empiric therapy may be limited in clinical practice, and narrow-spectrum empiric therapy may represent an effective treatment strategy for acute cholangitis.<\/jats:p>","DOI":"10.1371\/journal.pone.0346452","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:33:12Z","timestamp":1775151192000},"page":"e0346452","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical impact of broad- versus narrow-spectrum empiric therapy in acute cholangitis: A Japanese claims database study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2854-3929","authenticated-orcid":true,"given":"Kazuhiro","family":"Aoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Inose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6951-5676","authenticated-orcid":true,"given":"Yuichi","family":"Muraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"6","key":"pone.0346452.ref001","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/jhbp.452","article-title":"Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis","volume":"24","author":"H Gomi","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"pone.0346452.ref002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13054-021-03480-1","article-title":"Acute cholangitis in intensive care units: clinical, biological, microbiological spectrum and risk factors for mortality: a multicenter study","volume":"25","author":"J-R Lavillegrand","year":"2021","journal-title":"Crit Care"},{"issue":"3","key":"pone.0346452.ref003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1572-0241.2007.01095.x","article-title":"Epidemiology and prognostic determinants of patients with bacteremic cholecystitis or cholangitis","volume":"102","author":"C-C Lee","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"pone.0346452.ref004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jiac.2021.10.004","article-title":"Blood cultures should be collected for acute cholangitis regardless of severity","volume":"28","author":"T Otani","year":"2022","journal-title":"J Infect Chemother"},{"issue":"1","key":"pone.0346452.ref005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jhbp.509","article-title":"Tokyo guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis","volume":"25","author":"F Miura","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"pone.0346452.ref006","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update","volume":"18","author":"DL Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pone.0346452.ref007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"JDD Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"pone.0346452.ref008","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program","volume":"6","author":"M Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0346452.ref009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical infection society and the infectious diseases society of America","volume":"50","author":"JS Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pone.0346452.ref010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jhbp.518","article-title":"Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis","volume":"25","author":"H Gomi","year":"2018","journal-title":"J Hepatobil Pancreatic Sci"},{"issue":"4","key":"pone.0346452.ref011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2899","article-title":"Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use","volume":"3","author":"C Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pone.0346452.ref012","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac504","article-title":"Patterns, Predictors, and Intercenter Variability in Empiric Gram-Negative Antibiotic Use Across 928 United States Hospitals","volume":"76","author":"KE Goodman","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0346452.ref013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18923","article-title":"Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals","volume":"7","author":"C Rhee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"pone.0346452.ref014","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2005.08.016","article-title":"Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan","volume":"26","author":"P-R Hsueh","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0346452.ref015","article-title":"Correlation between antibiotic use and resistance of gram-negative bacteria at a university hospital in Japan from 2013 to 2021: a study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system","author":"K Kagami","year":"2023","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"pone.0346452.ref016","doi-asserted-by":"crossref","first-page":"1900057","DOI":"10.1183\/13993003.00057-2019","article-title":"Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study","volume":"54","author":"BJ Webb","year":"2019","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0346452.ref017","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40121-025-01142-1","article-title":"Effects of broad-spectrum antimicrobials on patients with community-acquired pneumonia with low risk for drug-resistant pathogens: historical cohort study in Japan","volume":"14","author":"T Takazono","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"5","key":"pone.0346452.ref018","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cid\/ciaf039","article-title":"Association between delayed broad-spectrum gram-negative antibiotics and clinical outcomes: how much does getting it right with empiric antibiotics matter?","volume":"80","author":"JD Baghdadi","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0346452.ref019","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jiac.2023.10.007","article-title":"Comparative effectiveness of cefmetazole versus carbapenems and piperacillin\/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study","volume":"30","author":"K Aoto","year":"2024","journal-title":"J Infect Chemother"},{"issue":"4","key":"pone.0346452.ref020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"S Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0346452.ref021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40780-025-00455-0","article-title":"Adherence to guidelines for antibiotics used in the initial treatment of febrile neutropenia in patients with cancer: a study using health insurance claims database in Japan","volume":"11","author":"K Mizuno","year":"2025","journal-title":"J Pharm Health Care Sci"},{"key":"pone.0346452.ref022"},{"key":"pone.0346452.ref023","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"SM Langan","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"pone.0346452.ref024","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"PD Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"11","key":"pone.0346452.ref025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"pone.0346452.ref026","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12879-024-09353-6","article-title":"Incidence and mortality of community-acquired and nosocomial infections in Japan: a nationwide medical claims database study","volume":"24","author":"N Takahashi","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pone.0346452.ref027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10","key":"pone.0346452.ref028","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmi.2017.02.027","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis: a retrospective cohort study","volume":"23","author":"Y Tagashira","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"pone.0346452.ref029","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"RM O\u2019Brien","year":"2007","journal-title":"Qual Quant"},{"issue":"19","key":"pone.0346452.ref030","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"RB Jr D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"12","key":"pone.0346452.ref031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program","volume":"62","author":"HS Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0346452.ref032","author":"Ministry of Health, Labour and Welfare"},{"issue":"10","key":"pone.0346452.ref033","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"PNA Harris","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"pone.0346452.ref034","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12879-020-4823-4","article-title":"The impact of diagnostic microbiology on de-escalation of antimicrobial therapy in hospitalised adults","volume":"20","author":"WL Hamilton","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0346452.ref035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jhin.2018.08.007","article-title":"Balancing the risks to individual and society: a systematic review and synthesis of qualitative research on antibiotic prescribing behaviour in hospitals","volume":"101","author":"EM Krockow","year":"2019","journal-title":"J Hosp Infect"},{"issue":"3","key":"pone.0346452.ref036","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/ice.2017.317","article-title":"Knowledge, attitudes, and practices regarding antimicrobial use and stewardship among prescribers at acute-care hospitals","volume":"39","author":"E Salsgiver","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"pone.0346452.ref037","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa298","article-title":"Barriers to adherence to antimicrobial stewardship postprescription review and feedback for broad-spectrum antimicrobial agents: a nested case-control study","volume":"7","author":"A Takamatsu","year":"2020","journal-title":"Open Forum Infect Diseases"},{"issue":"6","key":"pone.0346452.ref038","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf298","article-title":"Variability in durations of therapy for gram-negative bloodstream infections and factors associated with prolonged durations","volume":"12","author":"JD Sutton","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:33:18Z","timestamp":1775151198000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346452"}},"subtitle":[],"editor":[{"given":"Csaba","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346452","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}